United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $547.49, for a total transaction of $5,201,155.00. Following the sale, the chief executive officer owned 40,513 shares of the company’s stock, valued at approximately $22,180,462.37. This represents a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

United Therapeutics Stock Up 1.6%

UTHR opened at $553.14 on Wednesday. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35. The company has a 50 day moving average of $569.08 and a two-hundred day moving average of $520.18. The company has a market cap of $23.48 billion, a P/E ratio of 20.42, a P/E/G ratio of 1.77 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. During the same quarter in the prior year, the firm earned $6.63 earnings per share. United Therapeutics’s quarterly revenue was down 1.6% compared to the same quarter last year. Research analysts anticipate that United Therapeutics Corporation will post 26.84 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in UTHR. Torren Management LLC bought a new position in United Therapeutics during the 4th quarter valued at $26,000. Activest Wealth Management boosted its stake in United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares during the last quarter. WealthCollab LLC boosted its stake in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 38 shares during the last quarter. Rakuten Securities Inc. boosted its stake in United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 46 shares during the last quarter. Finally, Entrust Financial LLC bought a new position in United Therapeutics during the 4th quarter valued at $31,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on UTHR shares. Morgan Stanley set a $516.00 target price on shares of United Therapeutics in a research note on Thursday, May 7th. HC Wainwright upped their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Royal Bank Of Canada decreased their target price on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. Finally, UBS Group upped their target price on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $619.42.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.